Anemia has been reported with peginterferon alfa and
ribavirin therapy. The addition of INCIVEK to peginterferon alfa and
ribavirin is associated with an
additional decrease in hemoglobin concentrations. A decrease in hemoglobin levels occurred during the first 4 weeks of treatment, with lowest values reached at the end of INCIVEK dosing. Hemoglobin values gradually returned to levels observed with peginterferon alfa and ribavirin after INCIVEK dosing was completed.